SCHEMBL5050858

SCHEMBL5050858

CCCCCCCCCCCCC(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSK P43235 8/20 0.60
CTSS P25774 3/20 0.60
NOD1 Q9Y239 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7550254 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7839929 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL2706071 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL1926493 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7555645 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7550258 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7555646 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL6818249 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL7547359 1.00 CTSK (0.60) CTSKCTSSNOD1
SCHEMBL17356699 1.00 CTSK (0.60) CTSKCTSSNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 US disclosed
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 US disclosed
US-20080319375-A1 Materials, Methods, and Systems for Cavitation-mediated Ultrasonic Drug Delivery in vivo BIOVALUATION & ANALYSIS, INC. 2008-12-25 US disclosed
WO-2008157422-A1 MATERIALS, METHODS, AND SYSTEMS FOR CAVITATION-MEDIATED ULTRASONIC DRUG DELIVERY HARDY CHARLES THOMAS (US) 2008-12-24 WO disclosed
US-20080294089-A1 Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo BIOVALUATION & ANALYSIS, INC. 2008-11-27 US disclosed
WO-2002053572-A1 DELIVERY SYSTEMS ALCHEMIA PTY LTD (AU) 2002-07-11 WO disclosed
US-5128448-A Peptide hormones HOFFMAN-LA ROCHE INC. (US) 1992-07-07 US disclosed
EP-0413709-A4 FATTY AMINO ACIDS, AND HOMO- AND HETERO-OLIGOMERS AND CONJUGATES THEREOF GIBBONS WILLIAM ANTHONY (GB) 1991-12-27 EP disclosed
EP-0413709-A1 FATTY AMINO ACIDS, AND HOMO- AND HETERO-OLIGOMERS AND CONJUGATES THEREOF THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) 1991-02-27 EP disclosed
WO-1989010348-A1 FATTY AMINO ACIDS, AND HOMO- AND HETERO-OLIGOMERS AND CONJUGATES THEREOF SYNPHARM LTD (GB) 1989-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS PHOSPHO1, SGMS1, PLIN3 CTSK 3379/4885CTSS 3636/4885NOD1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.